Elevation of Serum Total Prostate-Specific Antigen (PSA) Level as Predictor of Prostate Cancer (PCa) of Patient Following Transurethral Resection of Prostate (TURP)

Authors

  • Muhammad Sidiq Division of Urology, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Jl. Kesehatan No. 1 Sinduadi, Mlati, Sleman PO 55281, Yogyakarta, Indonesia.
  • Trisula Utomo Division of Urology, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Jl. Kesehatan No. 1 Sinduadi, Mlati, Sleman PO 55281, Yogyakarta, Indonesia.
  • Wikan Kurniawan Division of Urology, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito General Hospital, Jl. Kesehatan No. 1 Sinduadi, Mlati, Sleman PO 55281, Yogyakarta, Indonesia.

DOI:

https://doi.org/10.30829/contagion.v7i1.23972

Abstract

Prostate cancer (PCa) is a significant global health issue, particularly in aging populations. In Indonesia, it is the fifth most common cancer. Diagnosis is often complicated by benign prostatic hyperplasia (BPH), which also elevates Prostate-Specific Antigen (PSA), limiting its specificity. This study aimed to establish an optimal preoperative PSA cutoff and assess the predictive utility of PSA, Neutrophil-Lymphocyte Ratio (NLR), and PSA Density (PSAD) for detecting PCa in patients undergoing Transurethral Resection of the Prostate (TURP). A retrospective cohort study analyzed 152 patients undergoing TURP at Gadjah Mada University Hospital (May 2018-July 2024) using a consecutive sampling method. Preoperative serum Total PSA, NLR, and PSAD were evaluated against postoperative histopathology. Bivariate and multivariate logistic regression were used to analyze relationships, while Receiver Operating Characteristic (ROC) curve analysis determined the optimal PSA cutoff. Prostate cancer was diagnosed in 19.1% of patients (n=29). ROC analysis identified a preoperative PSA cutoff of >19.95 ng/mL for predicting PCa, yielding an Area Under the Curve (AUC) of 0.863, with 75.9% sensitivity and 75.6% specificity. The multivariate analysis confirmed that elevated preoperative PSA (Odds Ratio [OR] 3.648), NLR (OR 3.868), and PSAD (OR 9.553) were all significant independent predictors of a PCa diagnosis. Among these, PSAD emerged as the strongest predictive marker. Preoperative serum PSA, NLR, and PSAD are valuable independent predictors for PCa in patients undergoing TURP for symptomatic BPH. A PSA cutoff of >19.95 ng/mL is a clinically relevant diagnostic threshold for this specific population. Employing a multi-marker panel, with particular emphasis on PSAD, can enhance risk stratification and help clinicians identify high-risk patients warranting further investigation for PCa when planning a TURP procedure.Keywords: Prostate Specific Antigen (PSA), Prostate Cancer (PCa), Benign Prostate Hyperplasia (BPH), Transurethral Resection of The Prostate (TURP)

References

Abedi, A. R., Ghiasy, S., Fallah-karkan, M., Rahavian, A., & Allameh, F. (2020). The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review. Research and Reports in Urology, Volume 12, 105-109. https://doi.org/10.2147/RRU.S245669

Adhyatma, K. P., Prapiska, F. F., Siregar, G. P., & Warli, S. M. (2019). Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio. Open Access Macedonian Journal of Medical Sciences, 7(10), 1628-1630. https://doi.org/10.3889/oamjms.2019.177

Anand, A., & Gupta, S. (2021). Prostate-specific antigen increase after urethral catheterisation: fact or myth. African Journal of Urology, 27(1), 43. https://doi.org/10.1186/s12301-021-00149-7

Anand Kumar, C., Amit Kumar, P., & Roshan, K. (2024). Histopathological Study of Prostatic Lesions in Transurethral Resection of Prostate Specimens in Correlation with Serum Prostate Specific Antigen Levels. International Journal of Health Sciences and Research, 14(3), 151-156. https://doi.org/10.52403/ijhsr.20240322

Awedew, A. F., Han, H., Abbasi, B., Abbasi-Kangevari, M., Ahmed, M. B., Almidani, O., Amini, E., Arabloo, J., Argaw, A. M., Athari, S. S., Atlaw, D., Banach, M., Barrow, A., Bhagavathula, A. S., Bhojaraja, V. S., Bikbov, B., Bodicha, B. B. A., Butt, N. S., Caetano dos Santos, F. L., … Dirac, M. A. (2022). The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity, 3(11), e754-e776. https://doi.org/10.1016/S2666-7568(22)00213-6

Benson, M. C., Seong Whang, I., Olsson, C. A., Mcmahon, D. J., & Cooner, W. H. (1992). The Use of Prostate Specific Antigen Density to Enhance the Predictive Value of Intermediate Levels of Serum Prostate Specific Antigen. Journal of Urology, 147(3 Part 2), 817-821. https://doi.org/10.1016/S0022-5347(17)37394-9

Cho, H. J., Shin, S. C., Cho, J. M., Kang, J. Y., & Yoo, T. K. (2014). The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen. Prostate International, 2(4), 196-202. https://doi.org/10.12954/PI.14060

Dany, Y. A., Hendri, A. Z., & Soerohardjo, I. (2021). Prostate cancer profile in Dr. Sardjito General Yogyakarta. Journal of Thee Medical Sciences (Berkala Ilmu Kedokteran), 53(3). https://doi.org/10.19106/JMedSci005303202104

Daryanto, B., Trianto, R., Seputra, K., & Purnomo, A. (2024). Evaluation of Cutoff Point Prostate Specific Antigen (PSA) and Prostate Specific Antigen Density (PSAD) in Patients with Suspected Prostate Cancer. Medical Archives, 78(1), 12. https://doi.org/10.5455/medarh.2024.78.12-15

Deshpande, N. S., Dahe, S. V., Munemane, A. B., Dhokikar, G. D., & Karle, R. R. (2020). Histopathological study of prostatic lesions in correlation with serum prostate specific antigen levels in elderly men. International Journal of Research in Medical Sciences, 8(9), 3304. https://doi.org/10.18203/2320-6012.ijrms20203683

Farha, M. W., & Salami, S. S. (2022). Biomarkers for prostate cancer detection and risk stratification. Therapeutic Advances in Urology, 14. https://doi.org/10.1177/17562872221103988

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778-789. https://doi.org/10.1002/ijc.33588

Kawahara, T., Fukui, S., Sakamaki, K., Ito, Y., Ito, H., Kobayashi, N., Izumi, K., Yokomizo, Y., Miyoshi, Y., Makiyama, K., Nakaigawa, N., Yamanaka, T., Yao, M., Miyamoto, H., & Uemura, H. (2015). Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget, 6(31), 32169-32176. https://doi.org/10.18632/oncotarget.5081

Luo, G., Guo, M., Liu, Z., Xiao, Z., Jin, K., Long, J., Liu, L., Liu, C., Xu, J., Ni, Q., & Yu, X. (2015). Blood Neutrophil-Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals of Surgical Oncology, 22(2), 670-676. https://doi.org/10.1245/s10434-014-4021-y

Neeli, S., Sharma, M., & Musale, A. (2021). Prostate-Specific antigen: An overview and its current status in the diagnosis of prostate cancer. Indian Journal of Health Sciences and Biomedical Research (KLEU), 14(1), 22. https://doi.org/10.4103/kleuhsj.kleuhsj_97_19

Nnabugwu, I., Udeh, E. ihechi, Otene, C., Nnabugwu, C., Ugwumba, F., & Enivwenae, O. (2014). Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making. Clinical Interventions in Aging, 89. https://doi.org/10.2147/CIA.S73814

Palestinian Ministry of Health. (2006). Guidelines for the management and care of diabetes mellitus: Quick reference guide. https://apps.who.int/iris/bitstream/handle/10665/119807/dsa698.pdf;jsessionid=47048D534701EC6D651C0DF3399B5338?sequence=1

Pellegrino, F., Tin, A. L., Martini, A., Vertosick, E. A., Porwal, S. P., Stabile, A., Gandaglia, G., Eastham, J. A., Briganti, A., Montorsi, F., & Vickers, A. J. (2023). Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? European Urology Focus, 9(2), 291-297. https://doi.org/10.1016/j.euf.2022.10.002

Rawla, P. (2019). Epidemiology of Prostate Cancer. World Journal of Oncology, 10(2), 63-89. https://doi.org/10.14740/wjon1191

Sandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021). Prostate cancer. The Lancet, 398(10305), 1075-1090. https://doi.org/10.1016/S0140-6736(21)00950-8

Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022). Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 27(17), 5730. https://doi.org/10.3390/molecules27175730

Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334-1357. https://doi.org/10.1161/hypertensionaha.120.15026

Wadgaonkar, A., Patil, A., Mahajan, S., & Yengantiwar, R. (2013). Correlation of serum prostate specific antigen (PSA) in benign prostate hyperplasia, prostatitis, serum prostate specific antigen (PSA), adenocarcinoma, Gleason score. International Journal of Basic and Applied Medical Sciences, 3(2), 274-281.

Wei, J. T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., Fine, S. W., Han, M., Kim, S. K., Kirkby, E., Konety, B. R., Miner, M., Moses, K., Nissenberg, M. G., Pinto, P. A., Salami, S. S., Souter, L., Thompson, I. M., & Lin, D. W. (2023). Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Journal of Urology, 210(1), 46-53. https://doi.org/10.1097/JU.0000000000003491

Wu, J., Pan, C. B., Xie, S. H., Tang, B., Fu, J., Wu, X., Tong, Z. G., Wu, B. W., Yang, Y. Q., Ding, H., Li, S. Y., & Hong, T. (2022). A propensity-adjusted comparison of endoscopic endonasal surgery versus transcranial microsurgery for pediatric craniopharyngioma: a single-center study. Journal of Neurosurgery: Pediatrics, 29(3), 325-334. https://doi.org/10.3171/2021.10.PEDS21392

Yusim, I., Krenawi, M., Mazor, E., Novack, V., & Mabjeesh, N. J. (2020). The use of prostate specific antigen density to predict clinically significant prostate cancer. Scientific Reports, 10(1), 20015. https://doi.org/10.1038/s41598-020-76786-9

Downloads

Published

2025-06-25

Issue

Vol. 7 No. 1 (2025): CONTAGION

Section

Articles

License

COPYRIGHT

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges as well as earlier and greater citation of published work (see The Effect of Open Access).
LICENSE

CONTAGION (Scientific Periodical Journal of Public Health and Coastal Health) is published under the terms of the Creative Commons Attribution-ShareAlike 4.0 International License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.